Adolf Hoess
Chief Executive Officer chez Affimed NV Niederlassung Deutschland
Fortune : 1 M $ au 31/03/2024
Profil
Adolf Hoess is currently the Chief Executive Officer and Chairman-Management Board at Affimed GmbH and Affimed NV Niederlassung Deutschland respectively.
He was previously the Chief Executive Officer & Director at Affimed NV, Chief Executive Officer at Jenowis AG, Director at Amphivena Therapeutics, Inc., Principal at Harvard University, Vice President-Licensing & Business Development at MorphoSys AG, General Manager & VP-Molecular Division at Carl Zeiss Jena GmbH, and Chief Commercial Officer at Shire Orphan Therapies GmbH.
He holds a doctorate degree from Technische Universität München and Ludwig-Maximilians-Universität München.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
AFFIMED N.V.
1,70% | 15/03/2023 | 253 593 ( 1,70% ) | 1 M $ | 31/03/2024 |
Postes actifs de Adolf Hoess
Sociétés | Poste | Début |
---|---|---|
Affimed NV Niederlassung Deutschland
Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Chief Executive Officer | - |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Chief Executive Officer | 01/09/2011 |
Anciens postes connus de Adolf Hoess
Sociétés | Poste | Fin |
---|---|---|
AFFIMED N.V. | Chief Executive Officer | 15/01/2024 |
Carl Zeiss Jena GmbH
Carl Zeiss Jena GmbH Medical SpecialtiesHealth Technology Carl Zeiss Jena GmbH engages in the design, prototyping, batch production, and testing of optical systems, single components, and auxiliary materials. It also provides services such as calibration, sampling of injection-molded and machined parts, hardness testing, heat treatment of materials, electromagnetic compatibility testing, and environmental simulation. The company is headquartered in Jena, Germany. | Corporate Officer/Principal | 01/01/2002 |
Harvard University
Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/01/1993 |
Jenowis AG | Chief Executive Officer | - |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Formation de Adolf Hoess
Technische Universität München | Doctorate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
AFFIMED N.V. | Health Technology |
MORPHOSYS AG | Health Technology |
Entreprise privées | 6 |
---|---|
Carl Zeiss Jena GmbH
Carl Zeiss Jena GmbH Medical SpecialtiesHealth Technology Carl Zeiss Jena GmbH engages in the design, prototyping, batch production, and testing of optical systems, single components, and auxiliary materials. It also provides services such as calibration, sampling of injection-molded and machined parts, hardness testing, heat treatment of materials, electromagnetic compatibility testing, and environmental simulation. The company is headquartered in Jena, Germany. | Health Technology |
Shire Orphan Therapies GmbH
Shire Orphan Therapies GmbH Pharmaceuticals: MajorHealth Technology Shire Orphan Therapies GmbH engages in the development, manufacture, and distribution of chemical and biochemical products, ingredients, as well as pharmaceutical and diagnostic products. The company was founded in 1994 and is headquartered in Berlin, Germany. | Health Technology |
Affimed NV Niederlassung Deutschland
Affimed NV Niederlassung Deutschland Pharmaceuticals: MajorHealth Technology Affimed NV Niederlassung Deutschland discovers and develops antibody-based therapeutic drugs. The firm generates and develops a pipeline of antibody product candidates based on proprietary technology platform. It offer therapeutic drugs that target autoimmune diseases and tumor cells. The company was founded in 2000 and is headquartered in Heidelberg, Germany. | Health Technology |
Amphivena Therapeutics, Inc.
Amphivena Therapeutics, Inc. Drugstore ChainsRetail Trade Amphivena Therapeutics, Inc. provides drug discovery services. It develops tetravalent, T-cell redirecting bispecific antibodies for the treatment of hematologic malignancies. The firm’s’ lead drug candidate is AMV-564, a CD33/CD3-targeting treatment for acute myeloid leukemia (AML), which Amphivena is currently preparing to advance into clinical development. The company was founded by Jeanmarie Guenot in December 2012 and is headquartered in San Francisco, CA. | Retail Trade |
Jenowis AG | |
Affimed GmbH
Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Commercial Services |